Coats on for Starpharma
Tuesday, 09 September, 2008
Starpharma [ASX: SPL] has licensed the marketing rights to its VivaGel coated condom to SSL International, owners of the market-leading Durex condom brand.
Under the agreement, SSL has been granted the right to marketing the VivaGel condom in most of the world, including Europe and the US.
The agreement could be worth at least $100 million in royalties, milestone payments and development support to Starpharma.
Starpharma is continuing to develop VivaGel as an applicator-delivered vaginal product designed to help women protect themselves from HIV and genital herpes.
Researchers genetically engineer snake antivenom
An international team of researchers has used genetic engineering to create so-called...
Common medications linked to adverse breast cancer outcomes
An international study has found concerning evidence about the impact of a range of common...
Saliva-based biosensor could improve heart failure detection
Scientists have created a biosensor that can rapidly detect the heart failure biomarker S100A7 in...
